Genmab — Marts 2017
-
Det var ikke længe den stigning holdt . https://baseballnewssource.com/markets/ishares-nasdaq-biotechnology-index-ibb-rating-increased-to-overweight-at-credit-suisse-group-ag/519403.html
-
Hele branchen ryster i bukserne. Tror ikke det har den store indflydelse på Gen i længden. http://www.fyens.dk/modules/mobile/article?articleid=3133459 Tror det er den "brede" medicin han sigter efter.
-
Også de brede indeks ryger ned nu. Så det virker som generel gevinsthjemtagning
-
Det er nu beskeden omsætning vi ser på faldet i Genmab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind